2023年8月21日,一品红(300723.SZ)发布关于创新药AR882进入全球Ⅲ期临床试验的公告。 一品红药业股份有限公司(以下简称“公司”)参股公司Arthrosi与FDA就创新药AR882Ⅱ期结束会议(EndofPhase2meeting,简称:EOP2;指申请人在Ⅱ期临床试验结束后,Ⅲ期临床试验前与药物监管机构共同召开的会议)沟通取得积极意见,并取得EOP2...
Tophi measurements with calipers were completed every 4 weeks for the first 6 months followed by every 3 months in the extension phase. DECT imaging was conducted at baseline, Months 6 and 12. Efficacy endpoints included change in sUA change from baseline and change from baseline in target ...
1.Xin Gao, Howard A. Burris III, Jacqueline Vuky, et al.Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).[J]. J Clin Oncol 40, ...
phase training to realize the improvements reliably. Our experimental results on a commonly used dataset show significant improvements, achieving average accuracy of 80.7% on the test set, which is more than 10.0% absolute improvement over existing models...
${mathrm{BaNi}}_{2}$${mathrm{As}}_{2}$, with a first-order phase transition around 131 K, is studied by the angle-resolved photoemission spectroscopy. The measured electronic structure is compared to the local-density approximation calcu... Z Bo,X Min,Z Yan,... - Electronic structure...
Objectives This global phase 2b trial is a randomized, double-blinded, placebo-controlled, 12-week study to evaluate the safety, tolerability, and efficacy of AR882 versus placebo in patients with gout. Methods The trial recruited patients 18 to 75 years of age with eGFR >30mL/min across 20...
Background: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout. In Phase 1 healthy subject studies, AR882 demonstrated good dose proportionality, a long effective half-life and sustained serum urate...
(MDCT). By adversarial learning in the MDCT domain, our method reconstructs HR speeches in a phase-aware manner without vocoders or additional post-processing. Furthermore, by learning frequency consistent features with self-attentive mechanism, mdctGAN...